Abstract: A process for making an essentially lead-free screw machine stock alloy, comprising the steps of providing a cast aluminum ingot having a composition consisting essentially of about 0.55 to 0.70 wt. % silicon, about 0.15 to 0.45 wt. % iron, about 0.30 to 0.40 wt. % copper, about 0.8 to 0.15 wt. % manganese, about 0.80 to 1.10 wt. % magnesium, about 0.08 to 0.14 wt. % chromium, nor more than about 0.25 wt. % zinc, about 0.007 to 0.07 wt. % titanium, about 0.20 to 0.8 wt. % bismuth, about 0.15 to 0.25 wt. % tin, balance aluminum and unavoidable impurities; homogenizing the alloy at a temperature ranging from about 900.degree. to 1060.degree. F. for a time period of at least 1 hour; cooling to room temperature; cutting the ingot into billets; heating and extruding the billets into a desired shape; and thermomechanically treating the extruded alloy shape.

Abstract: Can or lid stock and a method for its manufacture in which a low alloy content aluminum alloy is strip cast to form a hot strip cast feedstock, the hot feedstock is rapidly quenched to prevent substantial precipitation, annealed and quenched rapidly to prevent substantial precipitation of alloying elements and then cold rolled. The can end and tab stock of the invention has strength and formability equal to higher alloy content aluminum alloy.

Abstract: A method of producing an aluminum alloy having superplastic properties, including the steps of: heating the aluminum alloy; hot rolling to an exit temperature ranging from about 650.degree. to 70.degree. F.; and cold rolling to a gauge corresponding to a percentage of cold work selected from among those falling within the zone defined by the lines joining the points of A (475.degree. F., 10%), B (650.degree. F., 99%), C (70.degree. F., 99%) and D (70.degree. F., 10%), shown in FIG. 2, showing the relationship between the temperature range of the hot rolling exit temperature and the percent of cold work.

Abstract: Can or lid stock and a method for its manufacture in which a low alloy content aluminum alloy is strip cast to form a hot strip cast feedstock, the hot feedstock is rapidly quenched to prevent substantial precipitation and then cold rolled. The can end and tab stock of the invention has strength and formability equal to higher alloy content aluminum alloy.

Abstract: Peptides, that inhibit GAP stimulated ras p21 hydrolysis of GTP; peptides that mediate dissociation of GDP from ras p21-GTP complex; and antibodies to the peptides are described. These peptides are useful as cancer diagnostics and therapeutics, particularly to detect cancer cells with an over expression of normal or oncogenic ras p21 protein and to treat cancer caused by ras oncogene. Methods for assaying products of oncogenes using the described peptides and antibodies are also disclosed. Method for treating cancer caused by ras oncogenes is also disclosed.

Abstract: The present invention provides a filler alloy for brazing, which includes about 4 to 18 wt. % silicon; about 0.001 to 0.4 wt. % magnesium; about 0.01 to 0.3 wt. % lithium; not more than about 2 wt. % zinc; not more than about 1.25 wt. % manganese; not more than about 0.30 wt. % iron; not more than about 0.10 wt. % copper; not more than 0.15 wt. % impurities; balance aluminum.

Abstract: Method for removal of a liquid edge bead from the side marginal edges of a moving web, such as a strip. The method involves providing a moving web and two pair of manifolds, which are positioned above and below the top and bottom surfaces of the web, discharging a gas curtain approximately normal to the plane of the web, and introducing gas to the manifolds to produce a gas curtain from each manifold so that a portion of the gas curtains are deflected towards the edge of the web. The gas curtains that directly impact the web, in combination with a portion of the gas curtain that extends beyond the edge of the web and the portion that is created by the opposing gas curtain, create turbulence at the side marginal edges of the moving web to remove the liquid edge bead and to carry the liquid away from the marginal edges and the moving web.

Abstract: The invention relates to a fabrication process to obtain aluminum alloy sheet having high formability. In this process, an alloy obtained by alloying Al with Si, Mg, Cu, Mn and Fe, and one or more elements taken from the group of Cr, Zn, Zr and Ti, is subjected to a continuous solution treatment for at least 3 seconds at a temperature higher than 450.degree. C., followed by cooling to a temperature between 60.degree. and 250.degree. C., at a rate higher than 100.degree. C./min, followed by a coiling at the same temperature in the 60.degree. C.-250.degree. C. range and a preaging between 1 minute and 10 hours at the same cooling temperature of 60.degree. to 250.degree. C.

Abstract: DNA for new forms of CSF-1 are provided which relate to N-terminal and C-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the short and long forms of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 149.

Abstract: New forms of CSF-1 are provided which relate to N-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the long form of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 150.

Abstract: A method of producing an aluminum article comprising the steps of: (a) providing stock including an aluminum alloy comprising about 1.0 to 1.3 wt.% silicon, about 0.40 to 0.80 wt.% magnesium, about 0.02 to 0.20 wt.% of an element selected from the group consisting of manganese and chromium, not more than about 0.70 wt.% copper, the remainder substantially aluminum, incidental elements and impurities; (b) hot rolling the stock at a temperature ranging from about 980.degree. to 1025.degree. F. to obtain a gauge thickness ranging from about 0.20 to 0.10 inches; (c) solution heat treating at a temperature ranging from about 1000.degree. to 1030.degree. F. for a time period of about 3 to 10 minutes; (d) rapid quenching at a rate of about 500.degree. F./second to a threshold temperature of about 200.degree. F. for a time period ranging from about 2 to 10 minutes; (e) cooling to room temperature at a rate above 1.8.degree. F.

Abstract: The present invention relates to the production of CSF-1 heterodimers and pharmaceutical formulations of the heterodimers. The heterodimers can be formed using CSF-1 monomers that have variations in sequence, N or C-terminal processing. For example, CSF/C.gradient.150 can be dimerized with LCSF/C.gradient. 190 to form a heterodimer. Dimerization may occur by separately preparing homodimers and mixing them together under the appropriate conditions. Thereafter, homodimers may be separated from the heterodimers by various chromatographic techniques. Once the heterodimers are isolated, pharmaceutical preparations can be prepared.

Abstract: New forms of CSF-1 are provided which relate to N-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the short form of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 150.

Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in treating or preventing bacterial, viral or fungal infections, neoplasms, leukopenia, wounds, and in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.

Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in treating or preventing bacterial, viral or fungal infections, neoplasms, leukopenia, wounds, and in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.

Abstract: A process for recovering microbially produced IL-2 in a highly pure form from the cellular material of the microorganisms that produced it comprising: disrupting the-cell membranes of the microorganisms; extracting the disruptate with a chaotropic agent, such as urea, that selectively extracts microbial proteins from the cellular material; solubilizing the IL-2 in the solid phase of the extraction mixture with an aqueous solution of a solubilizing agent, such as SDS, containing a reducing agent; and separating the IL-2 from the resulting solution by an optional extraction with 2-butanol or 2-methyl-2-butanol followed by gel filtration chromatography, oxidizing the IL-2 and purifying the oxidized IL-2 by RP-HPLC.

Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.

Abstract: Multifunctional proteins having M-CSF activity and at least one other bioactivity not found together in a single naturally occuring molecule are described. These multifunctional M-CSF proteins can be produced by the expression of fused genes which are also described. These multifunctional M-CSF proteins have increased therapeutic potential.

Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in treating or preventing bacterial, viral or fungal infections, neoplasms, leukopenia, wounds, and in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.

Abstract: Recombinant vectors and methods for constructing ricin B are disclosed. The coding sequence for ricin B was cloned, disposed in suitable expression vectors and produced free of components normally accompanying this peptide. In addition, a novel means of reconstructing missing portions of coding sequence, and certain improvements in messenger RNA purification are disclosed.